EXAS · As filed with the SEC
Exact Sciences income statement, by fiscal year
The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2021 Year ended Dec 31, 2022 | FY2020 Year ended Dec 31, 2021 | FY2019 Year ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net loss | (207,949) | (1,028,857) | (204,149) | (623,506) | (595,625) | (823,605) |
| Net loss before tax | (203,888) | (1,036,161) | (201,746) | (632,570) | (842,506) | (829,063) |
| Loss from operations | (206,298) | (1,048,703) | (215,012) | (593,511) | (855,678) | (767,696) |
| Gross profit | 2,262,755 | 1,918,717 | — | — | — | — |
| Revenue | 3,246,990 | 2,758,867 | 2,499,766 | 2,084,279 | 1,767,087 | 1,491,391 |
| Cost of sales | 984,235 | 840,150 | 654,248 | 574,394 | 458,757 | 354,324 |
| Total operating expenses | 2,469,053 | 2,976,620 | — | — | — | — |
| Research and development | 522,996 | 431,210 | 425,882 | 393,418 | 385,646 | 554,052 |
| Sales and marketing | 1,050,183 | 894,125 | 727,090 | 846,011 | 861,889 | 589,919 |
| General and administrative | 888,674 | 781,825 | 893,204 | 737,304 | 801,262 | 481,393 |
| Amortization of acquired intangible assets | — | — | 92,160 | 97,450 | 95,001 | 93,398 |
| Impairment of long-lived assets | — | — | 621 | 15,969 | 20,210 | 209,666 |
| Total operating expenses | — | — | 2,793,205 | 2,664,546 | 2,622,765 | 2,282,752 |
| Impairment of long-lived and indefinite-lived assets | 7,200 | 869,460 | — | — | — | — |
| Other operating income | 0 | 9,200 | 78,427 | (13,244) | 0 | 23,665 |
| Total other income (expense) | 2,410 | 12,542 | 13,266 | (39,059) | 13,172 | (61,367) |
| Investment income, net | 41,771 | 39,558 | 32,713 | (19,425) | 31,778 | 6,574 |
| Interest expense | — | — | (19,447) | (19,634) | (18,606) | (67,941) |
| Interest Expense, Nonoperating | (39,361) | (27,016) | — | — | — | — |
| Income Tax Expense (Benefit) | (4,061) | 7,304 | (2,403) | 9,064 | 246,881 | 5,458 |
| Increase (decrease) in net loss per share (in usd per share) | (1.10) | (5.59) | (1.13) | (3.54) | (3.48) | (5.45) |
| Increase (decrease) in net loss per share (in usd per share) | (1.10) | (5.59) | (1.13) | (3.54) | (3.48) | (5.45) |
| Weighted average number of shares outstanding, basic (in shares) | 188,688 | 184,197 | 180,144 | 176,351 | 171,348 | 151,137 |
| Weighted average number of shares outstanding, diluted (in shares) | 188,688 | 184,197 | 180,144 | 176,351 | 171,348 | 151,137 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.